Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NMS-P088 |
Synonyms | |
Therapy Description |
NMS-P088 inhibits FLT3, KIT, and CSF1R with activity against FLT3 F691L, potentially leading to antitumor activity (Cancer Res (2023) 83 (8_Supplement): CT025). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NMS-P088 | NMS 03592088|NMS-03592088|NMS03592088|NMS P088|NMSP088 | CSF1R Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 | NMS-P088 inhibits FLT3, KIT, and CSF1R with activity against FLT3 F691L, potentially leading to antitumor activity (Cancer Res (2023) 83 (8_Supplement): CT025). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 act mut | acute myeloid leukemia | predicted - sensitive | NMS-P088 | Phase I | Actionable | In a Phase I trial, NMS-P088 demonstrated manageable safety and preliminary efficacy with responses in 5 of 12 patients with acute myeloid leukemia harboring FLT3 mutations (Cancer Res (2023) 83 (8_Supplement): CT025; NCT03922100). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03922100 | Phase Ib/II | NMS-P088 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Terminated | ITA | FRA | ESP | 0 |